Canada - français - Health Canada

boehringer ingelheim (canada) ltd ltee - vanillylnonamide; nicoboxil - pommade - 0.4%; 2.5% - vanillylnonamide 0.4%; nicoboxil 2.5% - basic lotions and liniments

Canada - français - Health Canada

roussel canada inc. - chloramphénicol; acétate d'hydrocortisone; nicoboxil; allantoïne; soufre - poudre - 40mg; 40mg; 24mg; 24mg; 320mg - chloramphénicol 40mg; acétate d'hydrocortisone 40mg; nicoboxil 24mg; allantoïne 24mg; soufre 320mg - antibiotics

Canada - français - Health Canada

hoechst roussel canada inc. - chloramphénicol; acétate d'hydrocortisone; nicoboxil; allantoïne; soufre - poudre pour solution - 40mg; 40mg; 24mg; 24mg; 320mg - chloramphénicol 40mg; acétate d'hydrocortisone 40mg; nicoboxil 24mg; allantoïne 24mg; soufre 320mg - anti-inflammatory agents

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

livisto int'l s.l. - firocoxib 227 mg - comprimé à croquer - 227 mg - firocoxib 227 mg - firocoxib - chien

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

livisto int'l s.l. - firocoxib 227 mg - comprimé à croquer - firocoxib

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

livisto int'l s.l. - firocoxib 56,75 mg - comprimé à croquer - 57 mg - firocoxib 56.75 mg - firocoxib - chien

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

livisto int'l s.l. - firocoxib 56,75 mg - comprimé à croquer - firocoxib

France - français - ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)

livisto int’l - firocoxib - comprimé à croquer

France - français - ANSES (Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail)

livisto int’l - firocoxib - comprimé à croquer

Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infections au vih - antiviraux à usage systémique - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.